Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.58 |
| ▸ | HTR2A | P28223 | 13/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5281553 | 0.99 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5498154 | 0.87 | SLC6A4 (0.50) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5500697 | 0.86 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL14624768 | 0.84 | SLC6A4 (0.48) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5502591 | 0.84 | SLC6A4 (0.60) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5501642 | 0.84 | TAAR1 (0.51) | HTR2AMAPT | |
| SCHEMBL5502053 | 0.83 | SLC6A4 (0.66) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL5457539 | 0.82 | TAAR1 (0.50) | HTR2A | |
| SCHEMBL5501242 | 0.81 | SLC6A4 (0.67) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5503685 | 0.80 | SLC6A4 (0.65) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | claimed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007010350-A1 | SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS | PFIZER PRODUCTS INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021634-A1 | SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS | PFIZER INC | 2007-01-25 | — | — | US | disclosed |
| US-20070021634-A1 | SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS | PFIZER INC | 2007-01-25 | — | — | US | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021634-A1 | SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS | DHFR, CYP2F1, EPOR | SLC6A4 4160/4885KCNH2 2220/4885HTR2A 2751/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885KCNH2 2331/4885HTR2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.